Gradual reduction of testosterone using a gonadotropin-releasing hormone vaccination delays castration resistance in a prostate cancer model

• Published in: Oncology letters Vol. 12; no. 2; pp. 963 - 970
• Main Authors: Barranco, Jesús A. Junco, Millar, Robert P, Fuentes, Franklin, Bover, Eddy, Pimentel, Eulogio, Basulto, Roberto, Calzada, Lesvia, Morán, Rolando, Rodríguez, Ayni, Garay, Hilda, Reyes, Osvaldo, Castro, Maria D, Bringas, Ricardo, Arteaga, Niurka, Toudurí, Henio, Rabassa, Mauricio, Fernández, Yairis, Serradelo, Andrés, Hernández, Eduardo, Guillén, Gerardo E
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.08.2016; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: adjuvant combination; Androgens; Antigens; Cancer therapies; Care and treatment; castration-resistant prostate cancer; Development and progression; Gonadotropin releasing hormone; gonadotropin-releasing hormone vaccination; Health aspects; hormone ablation; Immunoglobulins; Immunotherapy; Methods; Patient outcomes; Prostate cancer; prostate cancer vaccine; Proteins; Studies; Testosterone; Tumors; Vaccination; Vaccines; prostate cancer vaccine; castration-resistant prostate cancer; adjuvant combination; hormone ablation; gonadotropin-releasing hormone vaccination

In a previous study aimed to design a novel prostate cancer vaccine, the authors of the present study demonstrated the advantage of combining the adjuvants Montanide ISA 51 with very small size proteoliposomes (VSSP) to promote a significant humoral immune response to gonadotropin-releasing hormone...